How We Work

Kymab

Back

Print

CHALLENGE

Need for accelerated discovery, evaluation and translation of vaccines and immunotherapeutics for global health

PROGRAM STRATEGY

To fund cross-cutting R&D platforms across our major disease areas that disproportionately impact individuals living in developing countries:

  • Support novel technologies that enable therapeutic monoclonal antibody (mAb) generation, vaccine antigen discovery and vaccine immunogen iteration

PARTNER

Kymab
Biopharmaceutical company focused on the discovery and development of fully human mAb therapeutics using its transgenic mouse platform

Foundation focus: A fully humanized immunoglobulin mouse technology provides the ability: to test and iterate vaccine candidates in order to select those with a higher likelihood of success; to generate therapeutic mAb; and to generate human mAb for use in antigen discovery

INVESTMENT 

Series B preferred equity
Date: May 2014
Co-Investors: Wellcome Trust
Associated funding: Additional grant to malaria consortium for rapid identification of antigens for next-generation malaria vaccines

Visit Our Blog

Connect